Abstract
In the treatment of patients with lichen planus of the oral mucosa and identified papillomovirus infection, the appointment of an immunomodulatory drug with antiviral activity is of particular importance.Aim. To evaluate the clinical efficacy of antiviral and immunomodulatory drug inosine pranobex in the treatment of lichen planus of oral mucosa.Materials and methods. 49 patients with erosive-ulcerative form (37 women (75.5 %) and 12 men (24.4 %) aged 43 to 68 years, mean age 57.43 ± 2.53 years were under observation. The disease duration ranged from 6 months to 9 (5.58 ± 1.26) years.Results. Inosine pranobex, used in group Ib, showed high efficiency in the treatment of patients: the number of patients with high viral load decreased to zero, and the percentage of patients with clinically significant HPV decreased by half. Eradication of papillomavirus was recorded as a result of antiviral therapy in 11 (73.33 %) patients, while in group Ia such results were not achieved.Summary. According to the results of this study, it was found that for patients with lichen planus of oral mucosa with detected PVI, the appointment of an antiviral drug is necessary. This treatment is characterized by high efficiency and allows to increase the rate of epithelialization of pathological elements by almost 25 %, to achieve clinical remission and to stop the pain symptom faster, thereby improving the quality of life of patients.
Highlights
Gottlieb AB et al Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI‐1 and CIMPASI‐2). // J Am Acad Dermatol.— 2018.— 79, 2.— P. 302–314
In the treatment of patients with lichen planus of the oral mucosa and identified papillomovirus infection, the appointment of an immunomodulatory drug with antiviral activity is of particular importance
The disease duration ranged from 6 months to 9 (5.58 ± 1.26) years
Summary
Mrowietz U. et al Definition of treatment goals for moderate to severe psoriasis: A European consensus. Menter A. et al Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. Et al Guidelines of care for the management of psoriasis and psoriatic arthritis. Gottlieb AB et al Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks from 2 phase 3, multicenter, randomized, double-blinded, placebo-controlled studies (CIMPASI‐1 and CIMPASI‐2). Mease P. et al Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA). Оценка клинической эффективности применения противовирусного и иммуномодулирующего препарата инозин пранобекс в комплексной терапии КПЛ СОПР. По результатам данного исследования установлено, что для больных КПЛ на СОПР с выявленной
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
